The influence of sorafenib on hepatic encephalopathy and the mechanistic survey in cirrhotic rats
- 8 October 2012
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 42 (12) , 1309-1316
Abstract
Eur J Clin Invest 2012; 42 (12): 1309–1316 Background Sorafenib, a multikinase inhibitor that inhibits angiogenesis and carcinogenesis, has been used for patients with advanced hepatocellular carcinoma. However, sporadic cases have been reported with the development of hepatic encephalopathy (HE) after sorafenib treatment, mostly in those with cirrhosis. Liver function impairment, portal‐systemic collaterals and brain oxidative stress participate in the pathogenesis of HE. The study therefore aimed to investigate the potential influences of sorafenib on HE and the relevant risk factors in cirrhotic rats.Methods Liver cirrhosis was induced in Spraque‐Dawley rats with common bile duct ligation (CBDL). CBDL rats received sorafenib 1 mg/kg/day or distilled water (DW) via oral gavage since the 15th day post surgery for 2 weeks. On the 28th day, after motor activities measurements, mean arterial pressure, portal pressure and heart rate were checked. Thereafter, cerebral cortex and cerebellum were dissected for oxidative stress study and blood was collected for liver biochemistry survey.Results Sorafenib significantly reduced portal pressure (22%) and collateral shunting degree (15%) in cirrhotic rats. Alanine transaminase, aspartate transaminase, total bilirubin and ammonia were similar in sorafenib‐ and DW‐treated groups. Motor activities were not significantly altered by sorafenib. In cerebrum, the oxidant and antioxidant substances activities were not significantly different between the two groups, whereas they were divergent in cerebellum and hippocampus.Conclusion By surveying three main aspects involved in the pathogenesis of HE, this study demonstrates that sorafenib does not increase the risk of HE in cirrhotic rats.Keywords
This publication has 35 references indexed in Scilit:
- Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LARCell Death & Disease, 2011
- Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of SorafenibPLOS ONE, 2011
- Risk of Arterial Thrombosis Not Increased by Sorafenib or SunitinibJournal of Clinical Oncology, 2010
- Sorafenib-Induced Severe Acute Hepatitis in a Stable Liver Transplant RecipientTransplantation, 2010
- Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenibJournal of Experimental & Clinical Cancer Research, 2010
- Interaction of oxidative stress, astrocyte swelling and cerebral ammonia toxicityCurrent Opinion in Clinical Nutrition and Metabolic Care, 2010
- Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats #Hepatology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Pathogenetic mechanisms of hepatic encephalopathyGut, 2008
- The effects of ammonia and portal-systemic shunting on brain metabolism, neurotransmission and intracranial hypertension in hyperammonaemia-induced encephalopathyJournal of Hepatology, 1997